Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Italy

Research and Innovation Action · Running

BRYOMOLECULES Bioprospecting and production of bioactive molecules from European bryophytes

Coordinator
Fondazione Edmund Mach, Italy
Runs
1 September 2024 to 31 August 2027
Status
Running
EU funding
€3.6m
Total cost
€3.6m
Partners
8 organisations in 5 countries
Type
Research and Innovation Action
Grant agreement
101135305

What the project is doing

In the project's own words, from its summary on CORDIS.

Liverworts, an ancient group of land plants, are a rich and yet still underexploited source of a wide range of biologically active compounds with high potential for the bioeconomy sector as ingredients of cosmetics/cosmeceuticals and pharmaceutics. However, their slow growth rate in nature and the consequent difficulty to obtain large amounts of single compounds have until now severely hindered the in-depth exploration and exploitation of the full spectrum of activities of liverworts secondary metabolites.

Recent breakthroughs in the identification of some of the genes involved in the early steps of liverwort-specific compounds suggest that, in addition to the establishment of improved methods for growth in axenic conditions, reconstruction of liverwort metabolic pathways in heterologous systems is a promising way forth towards the practical exploitation of liverwort biochemical diversity and its industrial scale up. The BRYOMOLECULES project will use a combination of cultivation of axenic cultures and production of the active compounds in heterologous systems to define the most suitable production platform(s) for their large-scale production.

The project will achieve a very sustainable use of the chemical diversity of wild EU bryophyte species, a largely untapped source of high added-value natural products, without significant impacts on their biodiversity. Besides the identification of relevant lead compounds for cosmetics/cosmeceuticals and pharmaceutics , another major impact of the project will be the production and release according to FAIR principles of a database of metabolites and biosynthetic genes of European bryophyte species that will fuel in the years to come the development of novel bio-based products based on bryophyte-derived lead compounds, according to the concept of EU valorizing biodiversity for EU bioeconomy.

Topics

Who is involved

OrganisationCityCountryRole
Fondazione Edmund MachSan Michele All AdigeItalyCoordinator
Lab Analysis Life Science SLValenciaSpainParticipant
Fondation Europeenne De La ScienceStrasbourg CedexFranceParticipant
Plant Advanced Technologies Pat SAVandoeuvre Les NancyFranceParticipant
Universite Jean MonnetSaint-EtienneFranceParticipant
Fondazione Hub Innovazione TrentinoTrentoItalyThird party
Uniwersytet Medyczny W LublinieLublinPolandParticipant
Lunds UniversitetLundSwedenParticipant

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI